Welcome to the Jason Carter Clinical Trials Website
Our website helps patients find clinical trials. We currently offer patient-friendly descriptions of leukemia and lymphoma trials. Early in 2018, we will be:
Adding patient-friendly trial descriptions for other blood cancers and disorders
Making improvements to the search tool
Expanding our educational resources
Didn't find a trial or need help? Contact our clinical trial specialist at 888-814-8610 or contact@ctsearchsupport.org.
Two drugs, lenalidomide and rituximab, alone or with the drug tazemetostat to treat follicular lymphoma that has come back (relapsed) or has not gotten better with treatment (refractory)
To find out if the combination of lenalidomide, rituximab and tazemetostat is safe and works well to treat follicular lymphoma that has relapsed or is refractory compared to lenalidomide and rituximab alone
You may be able to join this trial if you:
Are 18 years old or older
Have follicular lymphoma that has relapsed or is refractory
Doctors consider the lymphoma grade 1, 2 or 3a
Have not been treated with lenalidomide. Your doctor can tell you this
Have not been treated with tazemetostat or other EZH2 inhibitors. Your doctor can tell you this
Do not have untreated lymphoma in your brain or spinal cord
You agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Lenalidomide is a drug that blocks growth of cancer cells. Rituximab is a monoclonal antibody that targets CD20 on certain cells. Tazemetostat is a small molecule inhibitor that blocks EZH2 in certain cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you and the clinical trial doctors won’t know which group you’re in until after the trial is finished:
Group 1 – Lenalidomide, rituximab plus tazemetostat
Group 2 – Lenalidomide, rituximab plus placebo
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You and the clinical trial doctors won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
You’ll get:
Lenalidomide – A pill that you take by mouth 1 time each day for the first 3 weeks of each month for 1 year
Rituximab – Given as intravenous (IV) infusions 1 time each week for 4 months
Tazemetostat (Group 1 only) – A pill that you take by mouth 2 times each day for 1 year
Placebo (Group 2 only) – A pill with no medicine in it that you take by mouth 2 times each day for 1 year
You’ll have scans to see how well treatment is working. The clinical trial doctors will check your health for up to 8 years.
The Food and Drug Administration (FDA) has approved all of the drugs in this trial to treat follicular lymphoma. Using them together in this way to treat follicular lymphoma that has relapsed or is refractory is new and unproven.
